CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Armed with what it sees as impressive clinical data and bolstered by long-standing ties to the Niemann-Pick disease type C ...

On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American ...

Since the introduction of the BIOSECURE Act in January, named companies and U.S.-based biopharmas alike have speculate | This ...

A nonprofit dedicated to improving vaccination rates to eradicate meningococcal meningitis is brightening things up this ...

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...

As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...